Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Paula Morlanes-Gracia"'
Autor:
Paula Morlanes-Gracia, Jorge Melero-Polo, Adrián Riaño-Ondiviela, Ana Martínez-Labuena, Sara C. Río-Sánchez, Daniel Meseguer-González
Publikováno v:
Archivos de Cardiología de México, Vol 91, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/91b58780188542b3a6b65778b5417363
Autor:
Paula Morlanes-Gracia, Guido Antoniutti, Jorge Alvarez-Rubio, Laura Torres-Juan, Damian Heine-Suñer, Tomás Ripoll-Vera
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
The NKX2-5 gene encodes for a transcription factor crucial for cardiac cell differentiation and proliferation. It was the first gene associated with congenital heart disease (CHD) in humans and has been linked to conduction disorders or cardiomyopath
Externí odkaz:
https://doaj.org/article/b905495d5aa342b4af447710524ba1fc
Autor:
Guido Antoniutti, Fiama Giuliana Caimi-Martinez, Jorge Álvarez-Rubio, Paula Morlanes-Gracia, Jaume Pons-Llinares, Blanca Rodríguez-Picón, Elena Fortuny-Frau, Laura Torres-Juan, Damian Heine-Suner, Tomas Ripoll-Vera
Publikováno v:
Genes, Vol 13, Iss 2, p 320 (2022)
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterised by increased left ventricle (LV) wall thickness caused by mutations in sarcomeric genes. Finding a causal mutation can help to better assess the proband’s risk, as it allows the p
Externí odkaz:
https://doaj.org/article/2b0695971db54b27bb8340542a79ddd9
Autor:
Pablo Revilla-Martí, Jose A. Linares-Vicente, Ana Martínez Labuena, Octavio Jiménez Melo, Paula Morlanes Gracia, Daniel Meseguer González, Antonela Lukic, Borja Simó Sánchez, Jose R. Ruiz Arroyo
Publikováno v:
Platelets, Vol 33, Iss 2, Pp 265-272 (2022)
Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting
Externí odkaz:
https://doaj.org/article/35a959876cd34b0b811d723065c368df
Autor:
José Antonio Linares Vicente, José Ramón Ruiz Arroyo, Antonela Lukic, Borja Simó Sánchez, Octavio Jiménez Melo, Adrián Riaño Ondiviela, Paula Morlanes Gracia, Pablo Revilla Martí
Publikováno v:
REC: Interventional Cardiology, Vol 4, Iss 1, Pp 12-18 (2022)
RESUMEN Introducción y objetivos: El uso de balón farmacoactivo (BFA) es una estrategia efectiva en el tratamiento de la reestenosis de stents coronarios (RIS). La modificación neointimal con balón de corte (BC) o incisión junto con BFA se asoci
Autor:
Adrián Riaño Ondiviela, Borja Simó Sánchez, Pablo Revilla Martí, Jose Antonio Linares Vicente, Antonela Lukic, Octavio Jiménez Melo, and Paula Morlanes Gracia, José R. Ruiz Arroyo
Publikováno v:
REC: Interventional Cardiology (English Ed.), Vol 4, Iss 1, Pp 12-18 (2022)
Introduction and objectives: Drug-eluting balloon (DEB) angioplasty is an effective technique to treat in-stent restenosis (ISR). Neointimal modification with cutting balloon (CB) or scoring balloon (SB) enhances the angiographic results of DEB, but
Autor:
Jose Ramón Ruiz Arroyo, Jose Antonio Linares-Vicente, Paula Morlanes Gracia, Antonela Lukic, Ana Martínez Labuena, Daniel Meseguer González, Borja Simó Sánchez, Octavio Jiménez Melo, Pablo Revilla-Martí
Publikováno v:
Platelets. 33:265-272
Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting
Autor:
Paula Morlanes-Gracia, Jorge Melero-Polo, Adrián Riaño-Ondiviela, Ana Martínez-Labuena, Sara C. Río-Sánchez, Daniel Meseguer-González
Publikováno v:
Archivos de cardiolog�a de M�xico (English ed. Internet). 91
Autor:
Guido, Antoniutti, Fiama Giuliana, Caimi-Martinez, Jorge, Álvarez-Rubio, Paula, Morlanes-Gracia, Jaume, Pons-Llinares, Blanca, Rodríguez-Picón, Elena, Fortuny-Frau, Laura, Torres-Juan, Damian, Heine-Suner, Tomas, Ripoll-Vera
Publikováno v:
Genes. 13(2)
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterised by increased left ventricle (LV) wall thickness caused by mutations in sarcomeric genes. Finding a causal mutation can help to better assess the proband's risk, as it allows the pre
Autor:
Sara C Río-Sánchez, Jorge Melero-Polo, Adrián Riaño-Ondiviela, Daniel Meseguer-González, Ana Martínez-Labuena, Paula Morlanes-Gracia
Publikováno v:
Archivos de Cardiología de México
Archivos de Cardiología de México, Vol 91, Iss 4 (2021)
Archivos de Cardiología de México, Vol 91, Iss 4 (2021)